1
|
Birge Ö, Bakır MS, Doğan S, Tuncer HA, Simsek T. Survival analysis and obstetric outcomes in patients with early stage ovarian cancer undergoing fertility-sparing surgery. J Ovarian Res 2022; 15:135. [PMID: 36564811 PMCID: PMC9783746 DOI: 10.1186/s13048-022-01082-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2022] [Accepted: 12/16/2022] [Indexed: 12/24/2022] Open
Abstract
OBJECTIVE The aim of the present study is to evaluate the long-term outcomes in patients with early stage ovarian cancer undergoing fertility-sparing surgery. METHODS The present study performed a retrospective analysis of recurrence, pregnancy and survival of a total of 66 patients who were diagnosed with early stage ovarian cancer (stage I) in XXX Faculty of Medicine Hospital between 2004 and 2019. Of these patients, 16 had undergone fertility-sparing surgery, and the remaining 50 patients had undergone radical surgery. RESULTS Of 66 eligible patients, 16 had undergone fertility-sparing surgery, and the remaining 50 patients had undergone radical complete surgery. When demographic and descriptive data are taken into consideration, the mean age was 32.6 ± 6.76 years in patients undergoing fertility-sparing surgery and 54.05 ± 10.8 years in patients undergoing complete surgery, and the difference between the groups was statistically significant (p = 0.001). Of patients undergoing fertility-sparing surgery, 11 (16.7%) had stage Ia disease (most common), 5 (7.5%) had stage Ic disease, whereas no patient with stage Ib disease was detected. Of patients undergoing complete radical surgery, 32 (48.5%) had stage Ia disease (most common), 1 (1.5%) had stage Ib disease with bilateral ovarian involvement, and stage Ic was the second most common disease stage. Also, stage Ic3 was the most common disease stage (8 patients, 12.1%) among those with stage Ic disease. The rate of recurrence was 4.5% (3 patients) in patients undergoing fertility-sparing surgery, and recurrences occurred at 37 months, 69 months, and 76 months, respectively. A patient with stage Ic3 disease and endometrioid type tumor who developed recurrence at 37 months died at 130 months. Of patients undergoing complete surgery, ten patients (15.2%) developed recurrence, and there was no significant difference between the two groups in terms of recurrence (p = 1.00). At the end of 15-year follow-up period, there was no significant difference between patients undergoing fertility-preserving surgery and those undergoing complete surgery in terms of mortality (p = 0.668). CONCLUSION The observation of significant findings in terms of the rate of recurrence and disease-free survival following fertility-sparing surgery in patients with low-risk early stage ovarian cancer suggests that survival is positively affected in early stage ovarian cancer.
Collapse
Affiliation(s)
- Özer Birge
- Department of Gynecology and obstetrics, Nyala Sudan Turkey Training and Research Hospital, West Alezza District Southern, 63311 Nyala, Darfur Sudan
| | - Mehmet Sait Bakır
- grid.29906.34Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey
| | - Selen Doğan
- grid.29906.34Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey
| | - Hasan Aykut Tuncer
- grid.29906.34Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey
| | - Tayup Simsek
- grid.29906.34Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey
| |
Collapse
|
2
|
Schuurman T, Zilver S, Samuels S, Schats W, Amant F, van Trommel N, Lok C. Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review. Cancers (Basel) 2021; 13:1008. [PMID: 33670929 DOI: 10.3390/cancers13051008] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Revised: 02/22/2021] [Accepted: 02/23/2021] [Indexed: 12/15/2022] Open
Abstract
Fertility-sparing surgery (FSS) is increasingly being offered to women with a gynecological malignancy who wish to preserve fertility. In this systematic review, we evaluate the best evidence currently available on oncological and reproductive outcome after FSS for early stage cervical cancer, epithelial ovarian cancer, and endometrial cancer. An extensive literature search was conducted using the electronic databases Medline (OVID), Embase, and Cochrane Library to identify eligible studies published up to December 2020. In total, 153 studies were included with 7544, 3944, and 1229 patients who underwent FSS for cervical, ovarian, and endometrial cancer, respectively. We assessed the different FSS techniques that are available to preserve fertility, i.e., omitting removal of the uterine body and preserving at least one ovary. Overall, recurrence rates after FSS are reassuring and therefore, these conservative procedures seem oncologically safe in the current selection of patients with low-stage and low-grade disease. However, generalized conclusions should be made with caution due to the methodology of available studies, i.e., mostly retrospective cohort studies with a heterogeneous patient population, inducing selection bias. Moreover, about half of patients do not pursue pregnancy despite FSS and the reasons for these decisions have not yet been well studied. International collaboration will facilitate the collection of solid evidence on FSS and the related decision-making process to optimize patient selection and counseling.
Collapse
|
3
|
Bartalot A, White M, Pejovict T, Tortoriello D, Nezhat FR. Conservative management of stage IIB ovarian carcinoma with favorable oncology and fertility outcomes. Gynecol Oncol Rep 2021; 35:100691. [PMID: 33521219 PMCID: PMC7820025 DOI: 10.1016/j.gore.2020.100691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2020] [Revised: 12/06/2020] [Accepted: 12/21/2020] [Indexed: 11/26/2022] Open
Abstract
•Fertility treatment prior to definitive cancer therapy in stage IIB EOC.•Both fertility and oncologic outcomes were successful.•The role of Multidisciplinary team is critical.
Collapse
Affiliation(s)
- Ashley Bartalot
- New York Presbyterian Brooklyn Methodist Hospital, 506 Sixth Street, Brooklyn, NY 11215, USA
| | - Michael White
- NYU Winthrop Hospital, 259 First Street, Mineola, NY 11501, USA
| | - Tanja Pejovict
- Oregon Health & Science University Hospital, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA
| | - Drew Tortoriello
- Sher Fertility Institute New York, 425 Fifth Ave., 3rd Floor, New York, NY 10016, USA
| | - Farr R Nezhat
- Nezhat Surgery for Gynecology/Oncology, 70 East Sunrise Highway, Suite 515W, Valley Stream, NY 11581, USA.,NYU Winthrop Hospital, 259 First Street, Mineola, NY 11501, USA.,Weill Cornell Medical College of Cornell University, 1300 York Ave., New York, NY 10065, USA
| |
Collapse
|
4
|
Subramanyeshwar Rao T, Raju KVVN, Gupta V, Rajagopalan Iyer R. Fertility preserving surgery in carcinoma ovary: a single institution experience. Indian J Gynecol Oncolog 2021. [DOI: 10.1007/s40944-020-00472-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Perri T, Harel G, Dadon T, Mor-Sasson A, Yagel I, Ben-Baruch G, Korach J. Frequency and prediction of deep uterine involvement in advanced high-grade epithelial ovarian cancer: is uterine preservation an option? Int J Gynecol Cancer 2020; 31:251-256. [PMID: 33172922 DOI: 10.1136/ijgc-2020-001850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Revised: 09/16/2020] [Accepted: 09/18/2020] [Indexed: 11/03/2022] Open
Abstract
INTRODUCTION Hysterectomy is traditionally part of the surgical treatment for advanced high-grade epithelial ovarian carcinomas, although the incidence of uterine involvement has not been fully investigated. Some young patients with advanced high-grade epithelial ovarian carcinomas want uterine preservation. We aimed to determine the frequency of non-serosal (deep) uterine involvement in patients with high-grade epithelial ovarian carcinomas and to establish predictive factors for such involvement. METHODS A retrospective cohort study was performed of 366 consecutive patients with advanced high-grade epithelial ovarian carcinomas who had surgery between January 2012 and December 2019. Data collected included demographic and clinical details, and surgical and pathological reports to determine macroscopic and microscopic deep uterine involvement. The characteristics of the patients with and without deep uterine involvement were compared and univariate and multivariate Cox proportional hazard models were used to assess correlations and determine risk factors. RESULTS A total of 311 patients were included in the final analysis. The mean age was 62±11.6 years, with 32 (10.3%) being younger than 45. Most (92.3%) had serous carcinoma. Uterine involvement, excluding superficial (serosa-only), was present microscopically in 194 patients (62.4%) but was detected macroscopically at surgery in only 166 patients. Deep involvement was missed at surgery in 28 patients (14.4%), including parametrial involvement (n=18), parametria plus cervix (n=2), cervical involvement (n=3), endometrium (n=3), and myometrium (n=2). Multivariate analysis identified factors associated with deep uterine involvement including residual disease at surgery (HR 2.43, 95% CI 1.13 to 4.48; p=0.004) and CA125 >1000 U (HR 1.8, 95% CI 1.09 to 2.94; p=0.02). CONCLUSIONS The incidence of deep uterine involvement in high-grade epithelial ovarian carcinomas is high. It can be diagnosed in most but not all cases on gross examination at surgery and is associated with residual disease and CA125 >1000 U. Patients who desire uterine preservation should be advised on an individual basis, given these factors and the operative findings.
Collapse
Affiliation(s)
- Tamar Perri
- Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel
- Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
| | - Gal Harel
- Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel
- Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
| | - Tal Dadon
- Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
| | - Aya Mor-Sasson
- Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel
- Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
| | - Itai Yagel
- Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel
- Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
| | - Gilad Ben-Baruch
- Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel
- Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
| | - Jacob Korach
- Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel
- Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
| |
Collapse
|
6
|
Gouy S, Saidani M, Maulard A, Bach-Hamba S, Bentivegna E, Leary A, Pautier P, Devouassoux-Shisheboran M, Genestie C, Morice P. Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers. Oncologist 2017; 23:324-327. [PMID: 29242280 DOI: 10.1634/theoncologist.2017-0310] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Accepted: 10/02/2017] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND No series had been reported focusing on the results of fertility-sparing surgery in stage I mucinous ovarian cancers according to histotype (infiltrative vs. expansile). Investigating such outcomes was the aim of the present study. MATERIALS AND METHODS The present study was a retrospective analysis of patients treated conservatively with preservation of the uterus and contralateral ovary from 1976 to 2016. The pathology of the tumors was reviewed by two expert pathologists according to the 2014 World Health Organization (WHO) classification criteria. Oncologic and fertility results were analyzed. RESULTS Twenty-one patients fulfilled the inclusion criteria, twelve with expansile and nine with infiltrative cancer. All patients had a unilateral tumor and underwent unilateral salpingo-oophorectomy in one-step (n = 6) or two-step (n = 15) surgeries. All but one had complete peritoneal staging surgery based on cytology, omentectomy, and random peritoneal biopsies. Ten had nodal staging surgery. The International Federation of Gynecology and Obstetrics stages were IA (n = 9), IC1 (n = 6), and IC2 (n = 6); the nuclear grades were grade 1 (n = 9), grade 2 (n = 5), and grade 3 (n = 1). Two patients recurred (one expansile and one infiltrative type) 19 and 160 months after surgery, respectively. One stage IA, nuclear grade 2 expansile tumor recurred on the spared ovary; the patient remains alive. The other stage IA infiltrative tumor recurred as peritoneal spread; the patient is alive with disease. Six patients became pregnant; four with expansile tumors and two with infiltrative tumors. CONCLUSION The type of mucinous cancer has no impact on the oncologic outcome in this series of patients treated conservatively. Fertility-sparing surgery should be considered for early-stage infiltrative-type tumors. IMPLICATIONS FOR PRACTICE According to the most recently updated World Health Organization classification guidelines, mucinous cancers should be classified as either expansile or infiltrative. The infiltrative type has a poorer prognosis, but there are no data about the safety of fertility-sparing surgery (FSS) in this context. A collection of 21 cases reviewed by two expert pathologists this study is the first devoted to the conservative treatment of mucinous tumors according to both subtypes. The key result was that the type of mucinous cancer has no impact on the oncologic outcome; thus, FSS may be considered in both subtypes.
Collapse
Affiliation(s)
- Sebastien Gouy
- Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France
| | - Marine Saidani
- Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France
| | - Amandine Maulard
- Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France
| | - Slim Bach-Hamba
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - Enrica Bentivegna
- Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France
| | - Alexandra Leary
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
- INSERM U981, Gustave Roussy, Villejuif, France
| | - Patricia Pautier
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | | | | | - Philippe Morice
- Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France
- Unit INSERM 1030, Villejuif, France
- University Paris Sud, Paris, France
| |
Collapse
|
7
|
Nishida K, Tenjimbayashi Y, Tasaka N, Shikama A, Sakuraiv M, Nakao S, Ochi H, Minaguchi T, Satoh T. Possible de novo clear cell carcinoma in the contralateral ovary 9 years after fertility-sparing surgery for Stage IA clear cell ovarian carcinoma. Int Cancer Conf J 2016; 6:50-54. [PMID: 31149470 PMCID: PMC6498281 DOI: 10.1007/s13691-016-0271-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Accepted: 11/13/2016] [Indexed: 11/28/2022] Open
Abstract
A patient who underwent fertility-sparing surgery for Stage IA clear cell carcinoma may have developed de novo clear cell carcinoma in the contralateral ovary 9 years later. She underwent fertility-sparing surgery and postoperative adjuvant chemotherapy for right ovarian carcinoma at 33 years of age (when endometriosis was observed in the contralateral ovary). At the age of 41 years, a tumor was discovered in the left ovary. This was diagnosed pathologically as clear cell carcinoma with clear cell adenofibroma, which may have developed de novo. A consensus is currently taking shape that although fertility-sparing surgery is a therapeutic option for patients with Stage IA clear cell carcinoma, long-term outpatient monitoring is advised to watch for its recurrence or de novo development in the contralateral ovary.
Collapse
Affiliation(s)
- K Nishida
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan
| | - Y Tenjimbayashi
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan
| | - N Tasaka
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan
| | - A Shikama
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan
| | - M Sakuraiv
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan
| | - S Nakao
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan
| | - H Ochi
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan
| | - T Minaguchi
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan
| | - T Satoh
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan
| |
Collapse
|
8
|
Bentivegna E, Gouy S, Maulard A, Pautier P, Leary A, Colombo N, Morice P. Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol 2016; 27:1994-2004. [DOI: 10.1093/annonc/mdw311] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Accepted: 07/26/2016] [Indexed: 11/14/2022] Open
|
9
|
Satoh T, Yoshikawa H. Fertility-sparing surgery for early stage epithelial ovarian cancer. Jpn J Clin Oncol 2016; 46:703-10. [PMID: 27284094 DOI: 10.1093/jjco/hyw069] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Accepted: 05/06/2016] [Indexed: 11/12/2022] Open
Abstract
Discussion of fertility-sparing treatment is an important part of pretreatment counseling for young patients with early epithelial ovarian cancer. As a result of late childbearing nowadays, fertility preservation has become a major issue in ovarian cancer patients. The purpose of this review is to update current knowledge on fertility-sparing treatment for early stage epithelial ovarian cancer, which may be useful for pretreatment counseling for reproductive-age patients. The multicenter study data on the fertility-sparing treatment published by Japan Clinical Oncology Group in 2010 confirmed that fertility-sparing surgery is a safe treatment for Stage IA patients with non-clear cell histology and Grade 1 or 2 and suggested that Stage IA patients with clear cell histology and Stage IC patients with non-clear cell histology and Grade 1 or 2 can be candidates for fertility-sparing surgery followed by adjuvant chemotherapy. In the current review, we added the recent case series and review, and discussed the fertility-sparing treatment on young patients with early epithelial ovarian cancer. We need not to change the proposal by the Japan Clinical Oncology Group study, but we should wait for the results of an ongoing prospective study to strongly recommend the proposal of the Japan Clinical Oncology Group study.
Collapse
Affiliation(s)
- Toyomi Satoh
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba
| | | |
Collapse
|
10
|
Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, Raspagliesi F. Fertility sparing surgery in early stage epithelial ovarian cancer. J Gynecol Oncol 2014; 25:320-7. [PMID: 25142621 PMCID: PMC4195303 DOI: 10.3802/jgo.2014.25.4.320] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2014] [Revised: 05/17/2014] [Accepted: 06/11/2014] [Indexed: 01/10/2023] Open
Abstract
Objective Fertility sparing surgery (FSS) is a strategy often considered in young patients with early epithelial ovarian cancer. We investigated the role and the outcomes of FSS in eEOC patients who underwent comprehensive surgery. Methods From January 2003 to January 2011, 24 patients underwent fertility sparing surgery. Eighteen were one-to-one matched and balanced for stage, histologic type and grading with a group of patients who underwent radical comprehensive staging (n=18). Demographics, surgical procedures, morbidities, pathologic findings, recurrence-rate, pregnancy-rate and correlations with disease-free survival were assessed. Results A total of 36 patients had a complete surgical staging including lymphadenectomy and were therefore analyzed. Seven patients experienced a recurrence: four (22%) in the fertility sparing surgery group and three (16%) in the control group (p=not significant). Sites of recurrence were: residual ovary (two), abdominal wall and peritoneal carcinomatosis in the fertility sparing surgery group; pelvic (two) and abdominal wall in the control group. Recurrences in the fertility sparing surgery group appeared earlier (mean, 10.3 months) than in radical comprehensive staging group (mean, 53.3 months) p<0.001. Disease-free survival were comparable between the two groups (p=0.422). No deaths were reported. All the patients in fertility sparing surgery group recovered a regular period. Thirteen out of 18 (72.2%) attempted to have a pregnancy. Five (38%) achieved a spontaneous pregnancy with a full term delivery. Conclusion Fertility sparing surgery in early epithelial ovarian cancer submitted to a comprehensive surgical staging could be considered safe with oncological results comparable to radical surgery group.
Collapse
Affiliation(s)
- Antonino Ditto
- Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.
| | - Fabio Martinelli
- Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy
| | - Domenica Lorusso
- Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy
| | - Edward Haeusler
- Department of Anesthesiology, IRCCS National Cancer Institute, Milan, Italy
| | | | | |
Collapse
|
11
|
Kim J, Kim KH, Mersereau JE. Building a successful fertility preservation program at a major cancer center. J Gynecol Oncol 2014; 25:148-54. [PMID: 24761219 PMCID: PMC3996265 DOI: 10.3802/jgo.2014.25.2.148] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2014] [Accepted: 02/23/2014] [Indexed: 01/11/2023] Open
Abstract
Over 150,000 reproductive age individuals face fertility-threatening cancer treatments each year. Improved detection and treatment of cancer in reproductive-age patients have greatly increased the long-term survival and made it possible for these individuals to consider their long-term quality-of-life after cancer including having biologic offspring. Various methods of fertility preservation (FP) are now available for both males and females. In order to maximize FP options available to patients facing imminent gonadotoxic therapies, it is crucial that women have quick access to FP care and that providers expedite FP strategies. The overarching goal of a clinical FP program is to help patients and their physicians consider the impact of treatment on future fertility and facilitate FP efforts in what is often a limited time period before cancer treatment begins.
Collapse
Affiliation(s)
- Jayeon Kim
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA
| | - Kenneth H Kim
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA
| | - Jennifer E Mersereau
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA
| |
Collapse
|
12
|
Petrillo M, Legge F, Ferrandina G, Monterisi A, Pedone Anchora L, Scambia G. Fertility-Sparing Surgery in Ovarian Cancer Extended beyond the Ovaries: A Case Report and Review of the Literature. Gynecol Obstet Invest 2014; 77:1-5. [DOI: 10.1159/000353277] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2013] [Accepted: 05/27/2013] [Indexed: 11/19/2022]
|
13
|
Arie AB, McNally L, Kapp DS, Teng NN. The omentum and omentectomy in epithelial ovarian cancer: A reappraisal. Gynecol Oncol 2013; 131:784-90. [DOI: 10.1016/j.ygyno.2013.09.013] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Revised: 09/09/2013] [Accepted: 09/11/2013] [Indexed: 12/25/2022]
|
14
|
Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, du Bois A, Petru E, Meier W, Ortner P, König K, Lindel K, Grab D, Piso P, Ortmann O, Runnebaum I, Pfisterer J, Lüftner D, Frickhofen N, Grünwald F, Maier BO, Diebold J, Hauptmann S, Kommoss F, Emons G, Radeleff B, Gebhardt M, Arnold N, Calaminus G, Weisse I, Weis J, Sehouli J, Fink D, Burges A, Hasenburg A, Eggert C. S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd 2013; 73:874-889. [PMID: 24771937 PMCID: PMC3859160 DOI: 10.1055/s-0033-1350713] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
15
|
Szatmári E, Máté S, Sipos N, Szánthó A, Silhavy M, Rigó J. [Methods and conditions of fertility preservation in early-stage ovarian tumors]. Orv Hetil 2013; 154:523-30. [PMID: 23545230 DOI: 10.1556/oh.2013.29581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The aim of this study is to review the literature of fertility-sparing techniques and their safety in early-stage malignant ovarian tumors, especially in epithelial ovarian cancer. Fertility preservation is widely accepted in early-stage borderline, germ cell and sex cord-stromal tumors. Based on data from retrospective studies, fertility-sparing surgery in epithelial ovarian cancer can be recommended in stage IA, grade 1-2 and favorable hystologic type ovarian cancer. Above stage IA, or in grade 3, or in clear-cell tumors decision making process about fertility-sparing surgery should be individual. Correct surgical staging is mandatory and oncologic safety should be of primary importance. In the group of carefully selected patients oncological outcomes are identical to those of radical surgery. Spontaneous pregnancy rates vary, but they are generally high. Adequate counseling with patients, detailed documentation and careful follow-up is of outstanding importance. In order to improve the quality of fertility preservation techniques, establishment of treatment centers is recommended.
Collapse
Affiliation(s)
- Erzsébet Szatmári
- Semmelweis Egyetem, Általános Orvostudományi Kar I. Szülészeti és Nőgyógyászati Klinika Budapest.
| | | | | | | | | | | |
Collapse
|
16
|
Abstract
For cancers of reproductive system in women, fertility preservation is complex. Fertility is also affected by therapies, however prevention is possible. Radiotherapy affects gonads, uterus, and subsequent pregnancy outcomes in all ages. However, degree and damage depend on dose, irradiation field, and age at the time of exposure. Ovarian transposition is considered if ovarian involvement is unlikely. Gonadotoxic effects of chemotherapy are related to agent's type, cumulative doses, age, and ovarian reserve. Some agents are highly toxic. Rendering follicular development quiescent by suppression of gonadotropins does reduce the ovarian damage. Simple or radical trachelectomy can be used in early cervical cancer. Fertility saving surgery is possible only in early stage low grade epithelial cancers of the ovary, however, in germ cell tumors even in advanced stages it may be possible to preserve fertility. There are no standard recommendations for endometrial cancer. Embryo, oocyte, and ovarian tissue cryopreservation are possible. The human embryo is very resistant to damage. In view of these possibilities, it is advocated that attention to long term health and quality of life in gonadotoxic therapy must be incorporated into plans as early as possible.
Collapse
Affiliation(s)
- Shakuntala Chhabra
- Obstetrics Gynecology, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra, India
| | - Imran Kutchi
- Obstetrics Gynecology, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra, India
| |
Collapse
|
17
|
|
18
|
Abstract
Ovarian cancer affects approximately 21,880 women and accounts for over 13,000 deaths annually in the United States. Although survival rates have improved over the past several decades, directly as a result of advances in chemotherapy and surgery, ovarian cancer continues to have high mortality rates. Understanding the multiple roles of surgery throughout the disease course is the focus of this review.
Collapse
|
19
|
Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol 2011; 205:103-10. [PMID: 21411052 DOI: 10.1016/j.ajog.2011.01.025] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2010] [Revised: 12/26/2010] [Accepted: 01/14/2011] [Indexed: 12/23/2022]
Abstract
A proportion of reproductive age women are affected by gynecologic malignancies. This patient population is faced with difficult decisions, related to their cancer care and treatment, as well as future childbearing potential. Therefore, it is important for gynecologists to be familiar with fertility sparing management options in patients with cervical, ovarian, and endometrial cancer. In addition to understanding the surgical approaches available, providers should be able to counsel patients regarding their eligibility for and the indications and limitations of fertility sparing therapy for gynecologic cancer, allowing for appropriate referrals. A comprehensive PUBMED literature search was conducted using the key words "fertility preservation," "cervical cancer," "endometrial cancer," "ovarian cancer," "borderline tumor of the ovary," "germ cell tumor," "obstetrical outcomes," "chemotherapy," and "radiation." The following review summarizes fertility sparing options for patients with cervical, ovarian and endometrial cancer, with an emphasis on appropriate patient selection, oncologic, and obstetric outcomes.
Collapse
|
20
|
Shyamala G. Conservative Approach in Gynecologic Malignancies. J Gynecol Surg 2010. [DOI: 10.1089/gyn.2009.0055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Guruvare Shyamala
- Department of Obstetrics and Gynecology, Kasturba Medical College, Manipal, India
| |
Collapse
|
21
|
Bisseling KCHM, Kondalsamy-Chennakesavan S, Bekkers RLM, Janda M, Obermair A. Depression, anxiety and body image after treatment for invasive stage one epithelial ovarian cancer. Aust N Z J Obstet Gynaecol 2010; 49:660-6. [PMID: 20070719 DOI: 10.1111/j.1479-828x.2009.01074.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Diagnosis of epithelial ovarian cancer (EOC) in young women has major implications including those to their reproductive potential. We evaluated depression, anxiety and body image in patients with stage I EOC treated with fertility sparing surgery (FSS) or radical surgery (RS). We also investigated fertility outcomes after FSS. METHODS A retrospective study was undertaken in which 62 patients completed questionnaires related to anxiety, depression, body image and fertility outcomes. Additional information on adjuvant therapy after FSS and RS and demographic details were abstracted from medical records. Both bi- and multivariate regression models were used to assess the relationship between demographic, clinical and pathological results and scores for anxiety, depression and body image. RESULTS Thirty-nine patients underwent RS and the rest, FSS. The percentage of patients reporting elevated anxiety and depression (subscores > or = 11) were 27% and 5% respectively. The median (interquartile range) score for Body Image Scale (BIS) was 6 (3-15). None of the demographic or clinical factors examined showed significant association with anxiety and BIS with the exception of 'time since diagnosis'. For depression, post-menopausal status was the only independent predictor. Among those 23 patients treated by FSS, 14 patients tried to conceive (seven successful), resulting in seven live births, one termination of pregnancy and one miscarriage. CONCLUSION This study shows that psychological issues are common in women treated for stage I EOC. Reproduction after FSS is feasible and led to the birth of healthy babies in about half of patients who wished to have another child. Further prospective studies with standardised instruments are required.
Collapse
|
22
|
Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, Yamaguchi S, Ochiai K, Takano M, Yokota H, Kawakami Y, Nishimura S, Ogishima D, Nakagawa S, Kobayashi H, Shiozawa T, Nakanishi T, Kamura T, Konishi I, Yoshikawa H. Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection. J Clin Oncol 2010; 28:1727-32. [DOI: 10.1200/jco.2009.24.8617] [Citation(s) in RCA: 147] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose The objective of this study was to assess clinical outcomes and fertility in patients treated conservatively for unilateral stage I invasive epithelial ovarian cancer (EOC). Patients and Methods A multi-institutional retrospective investigation was undertaken to identify patients with unilateral stage I EOC treated with fertility-sparing surgery. Favorable histology was defined as grade 1 or grade 2 adenocarcinoma, excluding clear cell histology. Results A total of 211 patients (stage IA, n = 126; stage IC, n = 85) were identified from 30 institutions. Median duration of follow-up was 78 months. Five-year overall survival and recurrence-free survival were 100% and 97.8% for stage IA and favorable histology (n = 108), 100% and 100% for stage IA and clear cell histology (n = 15), 100% and 33.3% for stage IA and grade 3 (n = 3), 96.9% and 92.1% for stage IC and favorable histology (n = 67), 93.3% and 66.0% for stage IC and clear cell histology (n = 15), and 66.7% and 66.7% for stage IC and grade 3 (n = 3). Forty-five (53.6%) of 84 patients who were nulliparous at fertility-sparing surgery and married at the time of investigation gave birth to 56 healthy children. Conclusion Our data confirm that fertility-sparing surgery is a safe treatment for stage IA patients with favorable histology and suggest that stage IA patients with clear cell histology and stage IC patients with favorable histology can be candidates for fertility-sparing surgery followed by adjuvant chemotherapy.
Collapse
Affiliation(s)
- Toyomi Satoh
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Masayuki Hatae
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Yoh Watanabe
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Nobuo Yaegashi
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Osamu Ishiko
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Shoji Kodama
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Satoshi Yamaguchi
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Kazunori Ochiai
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Masashi Takano
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Harushige Yokota
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Yosuke Kawakami
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Sadako Nishimura
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Daiki Ogishima
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Shunsuke Nakagawa
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Hiroaki Kobayashi
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Tanri Shiozawa
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Toru Nakanishi
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Toshiharu Kamura
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Ikuo Konishi
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| | - Hiroyuki Yoshikawa
- From the Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima; Department of Obstetrics and Gynecology, Tohoku University, Sendai; Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine; Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka; Department of Gynecology, Niigata Cancer Center Hospital, Niigata; Department of Gynecologic Oncology, Hyogo
| |
Collapse
|
23
|
Schlaerth AC, Chi DS, Poynor EA, Barakat RR, Brown CL. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19:1199-204. [PMID: 19823055 DOI: 10.1111/igc.0b013e31819d82c3] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
OBJECTIVE To determine the long-term results of fertility-sparing surgery in the treatment of early-stage invasive epithelial ovarian cancer. METHODS A retrospective review of 123 patients who underwent surgical staging for FIGO stage I epithelial ovarian cancer from November 1982 to July 2002. Demographics, stage, histopathology, adjuvant therapy, recurrence, and survival were compared for patients who had fertility-sparing surgery and for those having standard surgical staging. RESULTS Twenty patients, with a median age of 27 years, had preservation of the uterus and contralateral ovary at the time of surgical staging. Platinum-based chemotherapy was administered to 50% of these patients postoperatively. Three patients (15%) recurred in the retained ovary at 9, 20, and 22 months, and all died of their disease. One patient was diagnosed with primary endometrial cancer at 15 months and was salvaged with hysterectomy. At a median follow-up of 122 months, 17 (85%) of 20 patients treated with fertility-sparing surgery were alive without disease. Of the 103 patients treated with removal of the uterus and both ovaries, 72% received adjuvant platinum chemotherapy. Twenty (19%) of the patients in the standard surgery group have recurred, and 17 have died of disease. At a median follow-up of 113 months, 78 (76%) of 103 patients treated with standard surgery were alive without disease. Five-year survival data showed no significant difference in the recurrence-free survival of the fertility-sparing and standard surgery groups (84% vs 78%) or overall survival (84% vs 82%). CONCLUSION Fertility-sparing surgery is a reasonable alternative treatment for young women with stage I epithelial ovarian cancer desiring fertility preservation.
Collapse
Affiliation(s)
- Alan C Schlaerth
- Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
24
|
Abstract
Survival for cancer has improved significantly in the last 25 years with excellent overall 5- and 10-year survival rates. Hence, the majority of young women diagnosed with cancer can expect to live for decades, making quality of life issues such as fertility increasingly important. Risks of infertility vary based on the chemotherapy and treatments employed, as well as a woman's age. In general, younger women are less likely to experience permanent amenorrhea than older women, but even women who continue to menstruate have a greatly increased risk of premature menopause. Options for patients with cancer entering chemotherapy treatment, who wish to preserve fertility range from clinically well-established techniques such as embryo cryopreservation to more experimental techniques such as ovarian tissue cryopreservation. Pregnancy does not appear to increase the risk of cancer recurrence. Discussions of fertility issues in premenopausal women diagnosed with cancer present important challenges to the provider and to the patient. However, failure to discuss these options adequately can have lasting negative consequences on a woman's quality of life. Physician education interventions should seek to improve the knowledge of fertility preservations options, and of locally and nationally available resources.
Collapse
|
25
|
Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted? Gynecol Oncol 2009; 113:86-90. [DOI: 10.1016/j.ygyno.2008.12.007] [Citation(s) in RCA: 117] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2008] [Revised: 11/28/2008] [Accepted: 12/04/2008] [Indexed: 11/19/2022]
|
26
|
Morice P, Uzan C, Gouy S, Pautier P, Lhommé C, Duvillard P. Results of conservative treatment of epithelial ovarian tumor. Gynecol Oncol 2008; 112:673-4; author reply 674. [PMID: 18986689 DOI: 10.1016/j.ygyno.2008.09.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2008] [Accepted: 09/27/2008] [Indexed: 10/21/2022]
|
27
|
|
28
|
Abstract
The importance of quality-of-life (QOL) measurements in cancer management is being increasingly appreciated. This is especially important in patients with advanced cancers. Over 80% of women with epithelial ovarian cancer (EOC) will present with disease outside the ovary as there are no accurate screening tests, and symptoms usually do not develop until EOC has spread. Standard treatment includes debulking surgery followed by chemotherapy to which most women will have a complete response but only a minority of women with advanced disease will be cured. Fortunately, advances in surgical and chemotherapeutic management have improved overall survival with 45% of women of all stages living 5 years or longer. EOC may in many cases be considered a "chronic cancer," which highlights the importance of QOL in management decisions. QOL may be affected by the disease itself as well as by surgical and chemotherapeutic treatments. Future studies of the care and treatment of EOC patients should include well-designed QOL evaluations.
Collapse
|
29
|
Abstract
TheInternational Symposium on Advanced Ovarian Cancer: Optimal Therapywas founded by Dr. Andrés Poveda and Prof. Jan B. Vermorken, and each edition has been directed by them. The 6th edition was held on March 2, 2007. This symposium is organized every other year by GEICO (Grupo Español de Investigación de Cáncer de Ovario/Spanish Ovarian Cancer Research Group), under the auspices of the Spanish Society of Medical Oncology (SEOM), the Gynecologic Cancer Intergroup (GCIG), and the European Society of Medical Oncology (ESMO) Educational Committee for its Medical Oncology Recertification Approval (ESMO/MORA) Program. One hundred and fifty people attended the symposium's 1st edition, held in 1996. Since then, the interest in this meeting has increased. Last year, almost three hundred people coming not only from Spain but also from Europe, North and Latin America, Asia, and Australia were present in the symposium. This is a great challenge for us. Some important international cooperative groups from Europe, America, and Australia collaborate with this symposium, such as GOG, NCIC, EORTC, AGO, Scottish Group, ICON, GINECO, NSGO, ANZGOG, and others.
Collapse
|
30
|
Marpeau O, Schilder J, Zafrani Y, Uzan C, Gouy S, Lhommé C, Morice P. Prognosis of Patients Who Relapse after Fertility-Sparing Surgery in Epithelial Ovarian Cancer. Ann Surg Oncol 2007; 15:478-83. [DOI: 10.1245/s10434-007-9651-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2007] [Revised: 08/31/2007] [Accepted: 08/31/2007] [Indexed: 11/18/2022]
|
31
|
Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: A message of hope for young women. Gynecol Oncol 2006; 103:1109-21. [PMID: 16996582 DOI: 10.1016/j.ygyno.2006.08.003] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2006] [Revised: 07/19/2006] [Accepted: 08/04/2006] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Aggressive chemotherapy and radiotherapy or radical oncological surgery in young women with cancer has greatly enhanced these patients' life expectancy, but these treatments often cause infertility or premature ovarian failure due to a massive destruction of the ovarian reserve. The objective of this review is to discuss the effect of the various cancer treatments on fertility and present the various fertility sparing operations and fertility preservation strategies. METHOD An extensive survey of the most up-to-date literature was performed. RESULTS This review discusses the impact of current cancer treatment on fertility potential and the various surgical and assisted-reproduction innovations available today for the most common cancers in young women. Although the ability to retain reproductive potential is becoming a major quality-of-life factor in an increasing number of young female cancer survivors, they are still being poorly counseled with regard to the negative impact of the treatment on their fertility and on their options for fertility preservation. CONCLUSION As the emerging discipline of fertility preservation is steadily attracting increasing interest, developments in the near future promise to be very exciting. However, in everyday routine work, better interdisciplinary cooperation between gynecological and pediatric oncologists, surgeons, immunologists, and endocrinologists is necessary so that individualized options for fertility preservation can be offered in advance of surgical procedures or cancer treatments.
Collapse
Affiliation(s)
- Theodoros Maltaris
- Department of Obstetrics and Gynecology, Johannes Gutenberg University, Mainz University Hospital, Langenbeckstrasse 1, 55124 Mainz, Germany.
| | | | | | | | | |
Collapse
|
32
|
Abstract
PURPOSE OF REVIEW A European randomized trial on early stage ovarian cancer confirmed the importance of accurate staging to select candidates for adjuvant chemotherapy. Since early-stage disease is often discovered incidentally, staging is not always carried out or inadequately performed at the time of primary surgery. Laparoscopy was reported more than 10 years ago as a method of performing the staging procedure while avoiding the morbidity from a classical midline incision. RECENT FINDINGS Several teams have recently published their results on laparoscopic staging. Updated results of an earlier series in addition to other recent studies are discussed. All highlight the advantages and limits of the method. SUMMARY Complete laparoscopic management seems feasible in selected cases of apparently early stage ovarian cancer. Re-staging procedures remain an ideal indication for laparoscopy in early adnexal carcinomas. Due to the critical nature of the information obtained, this approach should only be reserved for teams trained in advanced laparoscopy.
Collapse
Affiliation(s)
- Eric Leblanc
- Department of Gynecological Oncology, Centre Oscar Lambret, Lille, France.
| | | | | | | | | |
Collapse
|
33
|
Abstract
Ovarian cancer (OC) is still the fourth cause of death by cancer among women and the most fatal among gynecological tumors. The purpose of the symposium held every 2 years in Valencia is to report and discuss new developments in the treatment of OC patients. It also tries to clarify what is evidence-based and what is not. In this issue, proteomic advances for early diagnosis and new tumor markers are presented. Controversies about the role of conservative surgery or the role of surgery in the recurrent disease are discussed. In addition, the current standard treatment, new tendencies on therapy, as well as important aspects related to the molecular era have been updated. Reaching international consensus is a challenge but offers the opportunity to test multiple regimens more efficiently against a single control population, rather than conducting multiple smaller studies. Most of the studies presented in this Symposium were carried out in Gynecologic Cancer Intergroup. If indeed answers to the relevant questions are to be obtained more quickly, then a network of current national or international groups could potentially facilitate this.
Collapse
Affiliation(s)
- A Poveda
- Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
| |
Collapse
|